New drug may treat and limit progression of Parkinson's disease

July 31, 2017
Immunohistochemistry for alpha-synuclein showing positive staining (brown) of an intraneural Lewy-body in the Substantia nigra in Parkinson's disease. Credit: Wikipedia

Researchers at Binghamton University have developed a new drug that may limit the progression of Parkinson's disease while providing better symptom relief to potentially hundreds of thousands of people with the disease.

Symptoms of Parkinson's disease are commonly managed using a selective dopamine receptor agonists. While these drugs are useful in early-stage Parkinson's, they tend to lose efficacy in later disease stages. As important, currently marketed drugs do not appear to modify disease progression. A research team including Binghamton University psychology professor Chris Bishop and former graduate student David Lindenbach recently employed a preclinical model of Parkinson's disease to compare the effects of the dopamine agonist ropinirole to their new , known as D-512. Results demonstrated that D-512 was more efficacious than ropinirole in treating the symptoms of Parkinson's disease while also prolonging the time window in which the animals showed benefits. These findings followed on the heels of prior work by this collaborative group which demonstrated that D-512 may also protect again the progression of Parkinson's disease.

"A major issue for Parkinson's disease patients is the need to take multiple medications, multiple times per day. So we were quite astounded to discover that our new compound, D-512, was superior to the widely-used drug, ropinirole, in terms of maximal and duration of action," said Lidenbach.

The researchers also noted that D-512 may have fewer side effects than current medications. When patients take anti-parkinsonian drugs, over time they develop hyperkinetic movements that are hard to control, called dyskinesia. Coupled with D-512's beneficial effects on motor symptoms, they argue that it therapeutic features are highly desirable.

"What you have is a better therapeutic index with our drug versus the current medication. And when you couple that with the fact that it's seemingly multifunctional...then what we have is a compound that just isn't currently available to Parkinson's patients but that we think has a lot of promise," said Bishop.

"D-512 is unique because it not only treats the symptoms of Parkinson's disease, but the molecule itself is an antioxidant," said Lindenbach. "This antioxidant property is important because a major cause of Parkinson's disease appears to be excessive oxidative stress is a small group of movement-facilitating brain cells."

The researchers are currently at a pre-clinical phase. Their goals are two-fold: to understand how D-512 actually provides neural protection and therapeutic relief, while also looking at different models of Parkinson's disease that will translate into the clinic.

"There are some intermediate steps that we may be involved in. I think one of these is determining whether this compound works in later stages to slow down the . It seems to work very well if you give it really early, before the disease takes hold—but looking at it at later time points and determining whether it can slow the down once it's really taken hold, also has important implications," said Bishop.

The paper, "D-512, a novel dopamine D2 / D3 receptor agonist, demonstrates superior anti-parkinsonian efficacy over ropinirole in parkinsonian rats," was published in The British Journal of Pharmacology.

Explore further: Researchers buoyed by molecule's potential to slow Parkinson's progress

More information: David Lindenbach et al, D-512, a novel dopamine D2 / D3 receptor agonist, demonstrates superior anti-parkinsonian efficacy over ropinirole in parkinsonian rats, British Journal of Pharmacology (2017). DOI: 10.1111/bph.13937

Related Stories

Researchers buoyed by molecule's potential to slow Parkinson's progress

January 26, 2017
A naturally occurring molecule in the brain, when used as a therapy, may hold a key to stopping the progression of Parkinson's disease, new research has found.

Feinstein announces submission of new drug application for diagnosing parkinsonian syndromes

November 14, 2012
The Feinstein Institute for Medical Research announced today the submission of a New Drug Application to the US Food and Drug Administration (FDA) for the Fluorodopa F 18 positron emission tomography (PET) scan used to diagnose ...

Breakthrough measures Parkinson's progression in the brain

May 26, 2015
University of Florida researchers have identified a biomarker that shows the progression of Parkinson's disease in the brain, opening the door to better diagnosis and treatment of the degenerative disease.

Blood biomarker could mark severe cognitive decline, quicker progression among Parkinson's patients

September 18, 2013
A genetic mutation, known as GBA, that leads to early onset of Parkinson's disease and severe cognitive impairment (in about 4 to 7 percent of all patients with the disease) also alters how specific lipids, ceramides and ...

Recommended for you

Data, technology drive new approaches to Parkinson's care

October 23, 2017
Complex, multi-system diseases like Parkinson's have long posed challenges to both scientists and physicians. University of Rochester Medical Center (URMC) researchers are now reaching for new tools, such as algorithms, ...

Investigating the most common genetic contributor to Parkinson's disease

October 19, 2017
LRRK2 gene mutations are the most common genetic cause of Parkinson's disease (PD), but the normal physiological role of this gene in the brain remains unclear. In a paper published in Neuron, Brigham and Women's Hospital ...

Scientists solve 3-D structure of key defense protein against Parkinson's disease

October 5, 2017
Scientists at the University of Dundee have identified the structure of a key enzyme that protects the brain against Parkinson's disease.

Novel protein interactions explain memory deficits in Parkinson's disease

September 26, 2017
A study published in the journal Nature Neuroscience describes the identification of a novel molecular pathway that can constitute a therapeutic target for cognitive defects in Parkinson's disease. The study showed that abnormal ...

Psychosis in Parkinson's dementia—new treatment provides hope

September 25, 2017
New research involving King's College London and the University of Exeter has highlighted the benefits of a promising new treatment which could relieve psychosis in thousands of people with dementia related to Parkinson's ...

Bicycling 'overloads' movement networks with Parkinson's

September 23, 2017
(HealthDay)—Bicycling suppresses abnormal beta synchrony in the Parkinsonian basal ganglia, according to a study published online Sept. 11 in the Annals of Neurology.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.